$Histogenics(OCGN)$ In my opinion (which obviously is not shared by many) today's news of India SEC approval for 2-18 year old's is bad news for Ocugen. Let me explain.

The plan this year is that Covaxin will be produced in India and then sent to Ocugen in the US for resale. Ocugen's CEO has mentioned that they could get 100 million doses from Bharat this year.

The problem is that Bharat wants to sell in India and other approved nations such as Iran, Mexico, Philippines, and many others. They especially would like a contact with COVAX (the WHO covid vaccine distribution initiative). Naturally, their last choice for vaccine distribution would be shipping to Ocugen where they give up 45% of their profits.

Today's SEC decision, gives Bharat a much bigger customer base in India, greatly reducing the chance that they have millions of extra doses to ship to Ocugen.

Not to offend people, but this is called due diligence.